Literature DB >> 20400818

Assessment of gold nanoparticles as a size-dependent vaccine carrier for enhancing the antibody response against synthetic foot-and-mouth disease virus peptide.

Yu-Shiun Chen1, Yao-Ching Hung, Wei-Hsu Lin, Guewha Steven Huang.   

Abstract

To assess the ability of gold nanoparticles (GNPs) to act as a size-dependent carrier, a synthetic peptide resembling foot-and-mouth disease virus (FMDV) protein was conjugated to GNPs ranging from 2 to 50 nm in diameter (2, 5, 8, 12, 17, 37, and 50 nm). An extra cysteine was added to the C-terminus of the FMDV peptide (pFMDV) to ensure maximal conjugation to the GNPs, which have a high affinity for sulfhydryl groups. The resultant pFMDV-GNP conjugates were then injected into BALB/c mice. Immunization with pFMDV-keyhole limpet hemocyanin (pFMDV-KLH) conjugate was also performed as a control. Blood was obtained from the mice after 4, 6, 8, and 10 weeks and antibody titers against both pFMDV and the carriers were measured. For the pFMDV-GNP immunization, specific antibodies against the synthetic peptide were detected in the sera of mice injected with 2, 5, 8, 12, and 17 nm pFMDV-GNP conjugates. Maximal antibody binding was noted for GNPs of diameter 8-17 nm. The pFMDV-GNPs induced a three-fold increase in the antibody response compared to the response to pFMDV-KLH. However, sera from either immunized mouse group did not exhibit an antibody response to GNPs, while the sera from pFMDV-KLH-immunized mice presented high levels of binding activity against KLH. Additionally, the uptake of pFMDV-GNP in the spleen was examined by inductively coupled plasma mass spectroscopy (ICP-MS) and transmission electron microscopy (TEM). The quantity of GNPs that accumulated in the spleen correlated to the magnitude of the immune response induced by pFMDV-GNP. In conclusion, we demonstrated the size-dependent immunogenic properties of pFMDV-GNP conjugates. Furthermore, we established that GNPs ranging from 8 to 17 nm in diameter may be ideal for eliciting a focused antibody response against a synthetic pFMDV peptide.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20400818     DOI: 10.1088/0957-4484/21/19/195101

Source DB:  PubMed          Journal:  Nanotechnology        ISSN: 0957-4484            Impact factor:   3.874


  36 in total

1.  Metallic Nanoparticles for Cancer Immunotherapy.

Authors:  Emily Reiser Evans; Pallavi Bugga; Vishwaratn Asthana; Rebekah Drezek
Journal:  Mater Today (Kidlington)       Date:  2017-12-14       Impact factor: 31.041

2.  Nanovaccines for malaria using Plasmodium falciparum antigen Pfs25 attached gold nanoparticles.

Authors:  Rajesh Kumar; Paresh C Ray; Dibyadyuti Datta; Geetha P Bansal; Evelina Angov; Nirbhay Kumar
Journal:  Vaccine       Date:  2015-08-20       Impact factor: 3.641

Review 3.  Convergence of nanotechnology and cancer prevention: are we there yet?

Authors:  David G Menter; Sherri L Patterson; Craig D Logsdon; Scott Kopetz; Anil K Sood; Ernest T Hawk
Journal:  Cancer Prev Res (Phila)       Date:  2014-07-24

4.  Electrically Oscillating Plasmonic Nanoparticles for Enhanced DNA Vaccination against Hepatitis C Virus.

Authors:  Mohamed Shehata Draz; Ying-Jie Wang; Frank Fanqing Chen; Yuhong Xu; Hadi Shafiee
Journal:  Adv Funct Mater       Date:  2016-12-14       Impact factor: 18.808

Review 5.  Role of Metallic Nanoparticles in Vaccinology: Implications for Infectious Disease Vaccine Development.

Authors:  Lázaro Moreira Marques Neto; André Kipnis; Ana Paula Junqueira-Kipnis
Journal:  Front Immunol       Date:  2017-03-08       Impact factor: 7.561

6.  Gold nanoparticle-M2e conjugate coformulated with CpG induces protective immunity against influenza A virus.

Authors:  Wenqian Tao; Katherine S Ziemer; Harvinder S Gill
Journal:  Nanomedicine (Lond)       Date:  2013-07-05       Impact factor: 5.307

7.  Designing inorganic nanomaterials for vaccines and immunotherapies.

Authors:  Krystina L Hess; Igor L Medintz; Christopher M Jewell
Journal:  Nano Today       Date:  2019-05-29       Impact factor: 20.722

8.  Conjugation of Y. pestis F1-antigen to gold nanoparticles improves immunogenicity.

Authors:  A E Gregory; E D Williamson; J L Prior; W A Butcher; I J Thompson; A M Shaw; R W Titball
Journal:  Vaccine       Date:  2012-09-18       Impact factor: 3.641

9.  Polyanhydride Nanovaccines Induce Germinal Center B Cell Formation and Sustained Serum Antibody Responses.

Authors:  Julia E Vela Ramirez; Lorraine T Tygrett; Jihua Hao; Habtom H Habte; Michael W Cho; Neil S Greenspan; Thomas J Waldschmidt; Balaji Narasimhan
Journal:  J Biomed Nanotechnol       Date:  2016-06       Impact factor: 4.099

10.  Robust IgG responses to nanograms of antigen using a biomimetic lipid-coated particle vaccine.

Authors:  Anna Bershteyn; Melissa C Hanson; Monica P Crespo; James J Moon; Adrienne V Li; Heikyung Suh; Darrell J Irvine
Journal:  J Control Release       Date:  2011-07-24       Impact factor: 9.776

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.